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Abstract
Aim To compare the prevalence of metabolic syndrome (MS) using the
World Health Organisation (WHO), Adult Treatment Panel III (ATPIII) and
International Diabetes Federation (IDF) criteria of MS in an urban south
Indian population, and their ability to identify coronary artery disease (CAD)
in males and females.
Methods Chennai Urban Rural Epidemiology Study (CURES) is one of the
largest epidemiological studies on diabetes carried out in India, in which
26 001 individuals aged ≥20 years were screened using systematic random
sampling method. Every tenth subject recruited in Phase 1 of CURES was
requested to participate in Phase 3, and the response rate was 90.4%.
An oral glucose tolerance test (OGTT) was performed in all individuals
except self-reported diabetic subjects. Anthropometric measurements and
lipid estimations were done in all subjects and the prevalence of MS estimated
using the three criteria. Diagnosis of CAD, made by resting 12 lead ECG, was
compared by the three criteria of MS.
Results MS was identified in 546 subjects (23.2%) by WHO criteria, 430
subjects (18.3%) by ATPIII criteria and 607 subjects (25.8%) by IDF criteria.
Only 224 of these subjects were identified by all the three criteria. There was
an increased risk of probable CAD in MS subjects diagnosed by WHO criteria
(odds ratio (OR) 3.86, 95% Confidence Interval (CI), 2.37–6.29, p < 0.001),
compared to ATPIII criteria (OR 2.19, 95% CI 1.30–3.67, p < 0.05) and IDF
criteria (OR 1.90, 95% CI 1.16–3.12, p < 0.05). The WHO criteria marked
out a much higher population for CAD risk compared to ATPIII and IDF
criteria in males, but not in females.
Conclusion In Asian Indians, the WHO, ATPIII and IDF criteria of MS
identify different individuals. The WHO criteria identify a greater number of
CAD subjects in males, but not in females. Copyright  2006 John Wiley &
Sons, Ltd.
Keywords metabolic syndrome; Asian Indians; WHO criteria; ATPIII criteria;
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Introduction
Metabolic syndrome (MS) refers to a clustering of metabolic risk factors
including central obesity, glucose intolerance, hyperinsulinemia, low HDL
Copyright  2006 John Wiley & Sons, Ltd.
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cholesterol, high triglycerides and hypertension [1].
People with MS are twice as likely to die from, and three
times as likely to develop, myocardial infarction (MI) or
stroke compared to people without MS [2]. They also have
a five-fold greater risk of developing type 2 diabetes (if not
already present) [3]. MS is increasingly being recognised
as a risk factor for cardiovascular disease (CVD) [2]
and cardiovascular mortality [4]. Unfortunately, there is
no internationally agreed definition for MS and, hence,
estimates of MS vary substantially across populations
depending on the criteria used. The World Health
Organisation (WHO) proposed a definition of MS in
1999 [5] and the National Cholesterol Education Program
Expert Panel (NCEP) and Adult Treatment Panel III
(ATPIII) published a working definition in 2001 [6].
Recently, the International Diabetes Federation (IDF)
Consensus group has come out with another definition
[7]. The aim of the present study is to compare the
prevalence of MS in an urban South Indian population
using the WHO, ATPIII and IDF definitions and their
ability to identify coronary artery disease (CAD) in males
and females. There are few reports on the prevalence of
MS using all three definitions and none from India, which
currently has the largest number of people in the world
with diabetes [8].
Study design
The Chennai Urban Rural Epidemiology Study (CURES)
is a large cross-sectional study done on a rep-
resentative population of the metropolitan city of
Chennai (formerly Madras) in southern India with
a population of 4.3 million people. The detailed
study design of CURES is described elsewhere [9]
and the sampling frame is shown in our website
http://www.mvdsc.org/mdrf/WORLD/pages/chennai.
html. Briefly, of the 155 Corporation wards in Chen-
nai, 46 wards were randomly selected to provide a total
sample size of 26 001 individuals ≥20 years of age. The
institutional ethical committee approval was obtained and
informed consent was obtained from all study subjects.
Phase 1 of CURES was conducted in the field and
involved a door-to-door survey of 26 001 individuals.
A detailed questionnaire was administered to all study
subjects to collect information regarding demographic,
socio-economic, behavioural and health status. A fasting
capillary blood sugar, blood pressure and basic anthropo-
metric measures were done in all eligible individuals.
Phase 2 of CURES deals with studies on the prevalence
of microvascular and macrovascular complications of
diabetes. Phases 1 and 2 are not discussed further in
this article.
In Phase 3 of CURES, every tenth subject recruited
in Phase 1 (n = 2600) was invited to our centre for
detailed anthropometric measurements and biochemical
tests. Of these, 2350 participated in the study (response
rate: 90.4%).
All the study subjects underwent an oral glucose tol-
erance test (OGTT) using a 75 g glucose load, except
self-reported diabetic subjects for whom fasting venous
plasma glucose (PG) was measured. The fasting blood
sample was taken, after ensuring 8 h of overnight fasting,
for estimation of PG and serum lipids using a Hitachi 912
Autoanalyser (Roche Diagnostics GmbH, Mannheim, Ger-
many) utilising kits supplied by Boehringer Mannheim
(Mannheim, Germany). Glycated hemoglobin (HbA1c)
was measured by the High-Pressure Liquid Chromatogra-
phy (HPLC) method using the Variant machine (BIORAD,
Hercules, California).
Anthropometric measurements including weight,
height, waist and hip measurements were obtained
using standardised techniques [9]. The blood pressure
was recorded in the right upper limb in the sitting
position, to the nearest 2 mmHg, using a mercury
sphygmomanometer (Diamond Deluxe BP apparatus,
Pune, India).
Definitions
Body mass index (BMI) was calculated using the
formula: weight (Kg)/height (m)2.
Waist circumference
The waist was measured using a non-stretchable fibre
measuring tape. The subjects were asked to stand erect
in a relaxed position with both feet together on a flat sur-
face; one layer of clothing was accepted. Waist girth was
measured as the smallest horizontal girth between the
costal margins and the iliac crests at minimal respiration.
Hip circumference
Hip measure was taken as the greatest circumference at
the level of greater trochanters (the widest portion of
the hip) on both sides. Measurements were made to the
nearest centimeter.
Waist and hip ratio (WHR) was calculated by dividing
waist circumference (cm) by hip circumference (cm).
Blood pressure was recorded in the sitting position
in the right arm, to the nearest 1 mmHg, using the
mercury sphygmomanometer. Two readings were taken
5 min apart and mean of the two was taken as the blood
pressure.
Diabetes
Diagnosis of diabetes was on the basis of the WHO
Consulting group criteria, that is, 2 h post load PG (2 h
PG) ≥11.1 mmol/L. Impaired glucose tolerance (IGT)
was diagnosed if the 2 h PG was ≥7.8 mmol/L and
<11.1 mmol/L and normal glucose tolerance (NGT) if
2 h PG was <7.8 mmol/L [10].
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Coronary artery disease (CAD)
A resting 12-lead electrocardiogram (ECG) was carried
out on 2199 subjects (response rate: 85%).
Possible CAD was diagnosed on the basis of a
documented past history of MI or drug treatment for
CAD and/or Minnesota codes 1-1-1 to 1-1-7 (Q-wave
changes), 4-1 to 4-2 (ST segment depression) or 5-1 to
5-3 (T-wave abnormalities).
Probable CAD was diagnosed on the basis of
documented history of MI or the presence of Q-waves
on ECG.
Criteria for metabolic syndrome
The three criteria used for defining MS are shown in
Table 1.
Insulin resistance for the WHO criteria was calculated
using the homeostasis assessment (HOMA) model using
the following formula: fasting insulin (µLU/mL) × fasting
glucose (mmol/L)/22.5. Subjects whose HOMA insulin
resistance values were above the 4th quartile for the
non-diabetic population (i.e. >2.58) were considered to
have insulin resistance (homeostasis assessment insulin
resistance (HOMA-IR)).
Statistics
Statistical analyses were performed using SPSS for
Windows version 10.0 software (SPSS Inc., Chicago,
Illinois). t tests were used for continuous variable and chi-
square test for proportions. Kappa (κ) statistics was used
for finding the agreement between the three definitions.
P-value <0.05 was considered significant.
Results
The mean age of the study population (n = 2350) was
40 ± 13 years and 47% (n = 1096) of the subjects were
males. Figure 1 shows that the prevalence and number
of individuals with MS were 23.2% (n = 546), 18.3%
(n = 430) and 25.8% (n = 607) according to the WHO,
ATPIII and IDF definitions respectively. Only 224 subjects
were identified to have MS by all three criteria. The
prevalence of MS was higher in females by ATPIII criteria
(males, 17.1%, females, 19.4%, p = 0.149) and IDF
criteria (males, 23.1%, females, 28.2%, p = 0.005), but
it was higher in males by WHO criteria (males, 27.3%,
females, 19.7%, p < 0.001).
Table 2 shows that subjects having MS according to
WHO criteria were older (47 ± 12 years; p < 0.05) and
had significantly lower BMI ( p < 0.05), waist ( p < 0.05)
and hip circumference ( p < 0.05) compared to those
with MS based on IDF and ATPIII criteria. Subjects
with MS based on IDF criteria had significantly lower
values of fasting PG ( p < 0.05) and glycated haemoglobin
( p < 0.05) compared to those with MS based on
ATPIII and WHO criteria. Mean serum triglyceride levels
WHO criteria
n = 546 (23.2%)
IDF criteria
n = 607 (25.8%)
NCEP ATPIII criteria







Figure 1. Venn diagram showing the overlapping of subjects
with metabolic syndrome based on the three definitions
Table 1. Definitions of the metabolic syndrome
Risk factors IDF consensus (2005) ATPIII criteria (2001) WHO criteria (1999)
1 Obesity/abdominal obesity Waist circumference ≥90 cm
(m), ≥80 cm (f) – South
Asians
Waist circumference
≥102 cm (m), ≥88 cm (f)
Body mass index (BMI)
≥30 kg/m2 and/or waist-to-hip
ratio >0.90 (m), >0.85 (f)
2 Blood pressure ≥130/≥85 mmHg ≥130/≥85 mmHg ≥140/≥90 mmHg or on
medication
3 Fasting glucose ≥5.6 mmol/L or pre-existing
diabetes
≥6.1 mmol/L or on
medication for diabetes
Diabetes, impaired glucose
tolerance or insulin resistance
4 Microalbuminuria Not used for diagnosis Not used for diagnosis Urinary albumin excretion rate
≥20 µg/min
5 Triglycerides ≥1.7 mmol/L ≥1.7 mmol/L Triglycerides ≥1.7 mmol/L and/or
HDL-C <0.91 mmol/L (m),
<1.01 mmol/L (f)




Metabolic syndrome – definition Abdominal obesity plus two
or more risk factors
At least three risk factors Diabetes, impaired glucose
tolerance or insulin resistance
plus any two or more risk factors
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Table 2. General characteristics of the subjects with metabolic
syndrome
Subjects with metabolic syndrome
Variables WHO IDF ATPIII
N 546 607 430
Male (%) 299 (54.8) 253 (41.7) 187 (43.5)
Age (years) 47 ± 12∗† 44 ± 11 45 ± 12
Body mass index
(kg/m2)
24.7 ± 3.5∗† 25.7 ± 3.1 25.6 ± 3.5
Waist circumference
(cm)
90.7 ± 9.1∗† 92.9 ± 7.7 92.7 ± 9.0
Hip circumference
(cm)
96.2 ± 8.3∗† 99.5 ± 7.3 98.9 ± 8.7
Waist-to-hip ratio 0.94 ± 0.08 0.94 ± 0.08 0.94 ± 0.08
Systolic blood
pressure (mmHg)
130 ± 21 129 ± 19 131 ± 17
Diastolic blood
pressure (mmHg)
81 ± 11 80 ± 11 81 ± 10
Fasting plasma
glucose (mmol/L)
7.0 ± 3.2∗ 6.2 ± 2.6 7.0 ± 3.3∗
Total cholesterol
(mmol/L)
5.13 ± 1.07 5.03 ± 0.98 5.09 ± 1.0
Triglycerides (mmol/L) 2.10 ± 1.32 1.98 ± 1.19 2.26 ± 1.30∗
HDL cholesterol
(mmol/L)
1.02 ± 0.23 1.02 ± 0.21 0.98 ± 0.19
LDL cholesterol
(mmol/L)
3.15 ± 0.95 3.09 ± 0.89 3.07 ± 0.91
HbA1C (%) 7.4 ± 2.1∗ 6.8 ± 1.7 7.4 ± 2.1∗
∗p < 0.05 compared to IDF criteria.
†p < 0.05 compared to ATPIII criteria
( p < 0.05) were higher in subjects with MS defined by
ATPIII criteria than by IDF criteria. Waist-to-hip ratio,
systolic and diastolic blood pressure, serum cholesterol
and HDL cholesterol did not differ in individuals identified
by the three criteria.
According to the WHO criteria, obesity was present in
57% (males, 65.8% and females, 49.4%), dyslipidemia in
41.7% (males, 46.7% and females, 37.4%), raised blood
pressure in 20% (males, 23.2% and females, 17.2%) and
microalbuminuria in 13.7% (males, 12.1% and females,
15.0%) of the study population.
Impaired fasting glucose (IFG) (including self-reported
diabetes) was detected in 20.9% (males, 24.2% and
females, 18.0%) and 14.7% of individuals (males, 17.8%
and females, 12.0%) on the basis of IDF and ATPIII
criteria respectively. Abdominal obesity was present in
49.2% (males, 38.5% and females, 58.3%) and 18.5%
(males, 6.2% and females, 29.2%) of the subjects on the
basis of IDF and ATPIII criteria, respectively. Raised blood
pressure was seen in 31.2% (males, 35.3% and females,
27.6%), increased triglycerides in 25.2% (males, 31.0%
and females, 20.1%) and decreased HDL cholesterol
levels in 63.5% (males, 55.4% and females, 70.6%) of
the subjects, which is similar using both ATPIII and IDF
criteria. It was also noted that 78.6%, 84.1% and 80.3%
of the subjects had at least one abnormality and 1.7%,
2.7% and 1.2% had all five abnormalities according to
WHO, IDF and ATPIII criteria, respectively (not shown in
table). The prevalence of MS increased with age until the
age of 69 and decreased thereafter in all three groups.
Even in the age group of 20–29 years, the prevalence of
MS ranged from 5.1–8.9% depending on the criteria used
to define MS (Figure 2).
The κ statistics for agreement between IDF with that of
ATPIII and WHO criteria were 0.58 ( p < 0.001) and 0.44
( p < 0.001), respectively. The agreement between ATPIII
and WHO criteria was 0.48 ( p < 0.001).
Possible coronary artery disease was present in 185
subjects (62 men, 33.5%), and 37.3%, 23.8% and 32.4%
of these subjects were identified by WHO, ATPIII and
IDF criteria, respectively. It is possible that subjects




























Figure 2. Prevalence of metabolic syndrome by age group
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may not have CAD because T-wave changes could
be nonspecific. Hence, further analyses were restricted
to those with documented MI or those who had Q-
waves (probable CAD). Probable CAD was present in
68 subjects (38 men, 55.9%), and 52.9%, 32.4% and
39.7% of these subjects were identified by WHO, ATPIII
and IDF definitions of MS, respectively. There was an
increased risk of CAD in subjects with MS diagnosed by
WHO criteria (odds ratio (OR): 3.86, 95% Confidence
Interval (CI), 2.37–6.29, p < 0.001), compared to MS
subjects diagnosed by ATPIII criteria (OR 2.19, 95% CI
1.30–3.67, p < 0.05) and IDF criteria (OR 1.90, 95% CI
1.16–3.12, p < 0.05) (Table 3). Of the male subjects with
‘possible’ or ‘probable’ CAD, the WHO criteria identified
56.5% and 63.2%, respectively, compared to 19.4%
and 23.7% by ATPIII criteria and 33.9% and 36.8%
by IDF criteria (Figure 3(a) and (b)). However, among
females, there was no difference in the identification
of CAD by the three criteria – ‘possible’ CAD (WHO
26.7%, ATPIII 26.0% and IDF 31.7%), ‘probable’ CAD
(WHO 40%, ATPIII 43.3% and IDF 43.3%), (Figure 3(a)
and (b)).
Table 3. Logistic regression analysis using coronary artery
disease (CAD) as an dependent variable and various MS criteria
as independent variables
MS Criteria ß S.E OR (95% CI) p-value
WHO criteria 1.352 0.248 3.86 (2.37–6.29) <0.001
ATPIII criteria 0.781 0.265 2.19 (1.30–3.67) 0.003
IDF criteria 0.642 0.253 1.90 (1.16–3.12) 0.011
Discussion
Different definitions of MS have been laid down by
the WHO, European Group for the Study of Insulin
Resistance (EGIR) ATPIII, American Association of
Clinical Endocrinologists (AACE), and the IDF. In the
present study, the most commonly used definitions of MS
(WHO, ATPIII and IDF) were used. These three definitions
agree on essential components – glucose intolerance,
obesity, hypertension and dyslipidemia – but they differ
in the cut-off points for the criteria of each component
of the cluster and the method of combining them to
define MS. The definition used in the WHO report centres
on diabetes and insulin resistance, whereas the ATPIII
guidelines give equal weightage to abdominal obesity,
hypertension, hyperglycemia, hypertriglyceridemia and
low HDL cholesterol. The IDF is closest to ATPIII in
that it includes the same variables, but it differs in
that central obesity is an essential component. Also,
the waist measurement is set at a lower level than in
ATPIII and it is ethnic-specific. The fasting hyperglycemia
is set at the new American Diabetes Association (ADA)
cut-off point for IFG. Moreover, it does not include any
measure of insulin resistance, and hyperglycemia is not
an obligatory component, which sets it apart from the
WHO and EGIR definitions. Although the prevalence of
MS varies according to the definition used, the WHO and
ATPIII definitions identify people at increased risk for
developing CVD and all the causes of mortality and for
developing diabetes [11].
(a)
(b) Overall Males Females
Overall Males Females
Figure 3. Identification of coronary artery disease by different criteria of metabolic syndrome
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Most of the earlier reports on MS have been based on
studies on Europeans. Asian Indians have very high rates
of diabetes [8] and premature CAD [12]. Also, different
waist cut-offs have been proposed for Asians [13]. The
IDF and WHO have called for more studies on MS using
different criteria for MS in different ethnic groups. This
study provides the first report on the prevalence of MS
among Asian Indians using the three definitions (WHO,
ATPIII and IDF). We found the prevalence of MS in our
study population to be 23.2%, 18.3% and 25.8% using
the WHO, ATPIII and IDF definitions, respectively.
Table 4 presents a survey of the literature showing
the prevalence of MS reported in different populations.
In previous studies, the prevalence of MS has varied
widely, primarily owing to different definitions of the
syndrome or selection of different subgroups. Very few
studies have been done in India on the prevalence of
MS and most were done using ATPIII criteria and one
study using EGIR criteria. The prevalence of MS in the
present study is much lower than that reported in an
earlier study in urban Indian adults aged 20–75 years, in
which the prevalence was reported to be 41.1% [14].
However, that study was done in a smaller sample
size (n = 475), used the modified ATPIII criteria and
excluded self-reported diabetic subjects. The age-adjusted
prevalence of MS based on ATPIII criteria in Jaipur (urban
North Indian population) was 24.9% [15]. In the Chennai
Urban Population Study (CUPS), the prevalence of MS
as defined by EGIR was found to be 11.2% (18.7% in
the middle-income and 6.5% in the low-income groups),
showing a significant difference even within an urban
environment in different socio-economic groups [16].
Results of the Singapore National Health Survey shows
a higher prevalence of MS among the Asian Indians
(28.8%) compared to Malays (24.2%) and Chinese
(14.8%) [21]. It is noteworthy that the prevalence rates
Table 4. Prevalence of metabolic syndrome from various studies




size MS prevalence (%)
Diagnostic
criteria
Abdul-Rahim HF, Palestinian 1996–1998 30–65 Urban:492 17%a WHO
et al., 2001 [17] Rural: 500
Ford ES, 2003 [11] US 1988–1994 ≥20 8608 ATPIII − 23.9%b;
WHO − 25.1%b
ATPIII & WHO
Al-Lawati JA, et al.,
2003 [18]
Nizwa City, Oman 2001 ≥20 1419 17%a; 21%b ATPIII




1988 45–74 2283 35%a ATPIII
Azizi F, et al., 2003
[20]
Tehran, Iran 1999–2001 ≥20 9846 30.1%a; 33.7%c ATPIII
Tan CE, et al., 2004
[21]




Oh J, et al., 2004 [22] Korea 1997 30–80 655 Men: 29%a; Women: 16.8%a ATPIII [modified]
Ilanne-Parikka P,
et al., 2004 [23]
Finland 1992 45–64 2049 Men: 38.8%a; Women:
22.2%a
WHO
Jaber LA, et al., 2004
[24]
Michigan, US 20–75 542 ATPIII: 23%b; WHO: 28%b ATPIII & WHO
Thomas GN, et al.,
2005 [25]
Hong Kong 1994–1996 25–74 2843 21.9%c ATPIII [modified]
Son LNTD, et al.,
2005 [26]
Ho Chi Minh City,
Vietnam
2001 ≥20 611 18.5%a; 12.0%c ATPIII
Gu D, et al., 2005 [27] China (Inter-ASIA) 2000–2001 35–74 15 540 Men: 9.8%c; Women: 17.8%c ATPIII
Ford ES, 2005 [28] United States. 1999–2002 ≥20 3601 ATPIII: 34.5%a; IDF: 39.0%a ATPIII & IDF
Ko GT, et al., 2005
[29]
Hong Kong 18–66 1513 WHO: 13.4%a; EGIR: 8.9%a;
ATPIII: 9.6%a
WHO, EGIR & ATPIII
[modified]
Adams RJ, et al., 2005
[30]
South Australia ≥18 4060 IDF: 22.8%a; ATPIII:15%a IDF & ATPIII
Guerrero-Romero F,
et al., 2005 [31]
Northern Mexico
(Durango City)
30–64 700 IDF:22.3%a; ATPIII:22.6%a;
WHO: 15.4%a
IDF, ATPIII & WHO












1989–1990 ≥65 2175 ATPIII: 28.1%a; WHO: 21%a ATPIII & WHO
Bo S, et al., 2005 [34] North-western Italy 2001–2003 45–64 1877 23.1%a ATPIII
Mohan V, et al., 2001
[16]
Chennai, India 1996–1997 ≥20 1262 11.2%a EGIR
Ramachandran A,
et al., 2003 [14]
Chennai, India 1995 20–75 475 41.1%a ATPIII [modified]
Gupta R, et al., 2004
[15]
Jaipur, India ≥20 1091 31.6%a; 24.9%b ATPIII
Present Study Chennai, India 2002–2004 ≥20 2350 WHO: 23.2%a; ATPIII:
18.3%a; IDF: 25.8%a
WHO, ATPIII & IDF
Prevalence of metabolic syndrome: aCrude prevalence.
bAge-adjusted prevalence; cAge standardised prevalence rate.
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among Indians in Singapore are similar to the rates in the
present study done on urban Indians. The National Health
and Nutrition Examination Survey (NHANES) III in the
United States shows an age-adjusted prevalence of MS in
23.7% as defined by ATPIII criteria [35]. The prevalence
of MS in a subgroup of older participants (≥60 years)
from a Cardiovascular Health Study (CHS) was 28.1%
by ATPIII criteria and 21.0% by WHO criteria [33]. The
MS prevalence among workers aged 30–60 years using
ATPIII criteria was reported to be 12% for Japanese, 13%
for Koreans and 16% for Mongolians [32]. In the United
States, 39% of adults were classified as having MS using
the IDF criteria, a figure that is higher than that estimated
by the ATPIII definition (34.5%) [29]. Similarly, in a study
done in South Australia, the prevalence of MS was higher
using the IDF criteria (22.8%) as compared to ATPIII
criteria (15%) [30]. This is consistent with the present
study, in which the prevalence of MS based on IDF criteria
is higher (25.8%) than that estimated by ATPIII criteria
(18.3%).
We also found that the prevalence of MS increased
with age irrespective of the definitions used. It is
noteworthy that 5.1–8.9% of the subjects in the age group
20–29 years had MS, depending on the definition used.
The higher prevalence of MS at younger ages in Asian
Indians is of particular concern, as it means that they will
have a more prolonged exposure to the atherosclerotic
risk factors associated with MS. Studies have shown that
prolonged exposure to atherosclerotic risk factors before
the onset of diabetes could also contribute to the excess
mortality in Asian Indians, which was observed in a study
that compared Indians, Malays and Chinese [36].
In the present study, the concordance of subjects with
MS based on IDF criteria with that of ATPIII and WHO
was 0.58 and 0.44, respectively, and only 224 subjects
were deemed to have MS based on all three criteria.
A study in northern Mexico had shown that the IDF
has a high concordance (0.87) with ATPIII definition,
identifying similar proportions of subjects with MS and a
low concordance (0.51) with the WHO definition. Results
of the Cardiovascular Health Study (CHS) show an 80%
concordance in classifying subjects by ATPIII and WHO
criteria [33]. In the Hoorn study, 60–80% agreement was
noted among various definitions such as ATPIII, WHO,
EGIR and AACE [37]. Thus, the agreement between
different definitions of MS appears to vary in different
ethnic groups, which is likely due to the different cut-
off points used. Despite the fact that the three criteria
share most of the components, they still misclassify a
large number of subjects as having MS in this urban south
Indian population.
To examine the definition of MS that was more
strongly associated with the risk for CVD, we compared
the correlation of CAD with MS defined by the three
definitions. Overall, the prevalence of CAD was four times
higher in subjects with MS diagnosed using the WHO
criteria, whereas it was two-fold higher on the basis
of IDF and ATPIII criteria. The possible explanation is
that since insulin resistance is included as one of its
criteria, the WHO definition may identify people who
are more insulin resistant than the other two criteria.
Another interesting observation is that the WHO criteria
mark out a higher population for CAD risk in males but
not in females. The possible explanation for this is that
metabolic abnormalities associated with insulin resistance
tend to cluster more in males than in females. Lehto et al
[38] have shown that metabolic abnormalities predict
CAD better in males than in females.
The strengths of the present study are that the subjects
studied are representative of the urban population of
Chennai, the sample size is large (n = 2350) and the
response rate is very good (90.4%). However, the cross-
sectional nature of the design does not allow for cause-
effect conclusions to be made.
In conclusion, we report that in this urban adult
Asian Indian population, a high prevalence of MS
(approximately one-quarter of adults) is seen using all
three criteria, although they seem to identify different
individuals. Among men, the WHO MS criteria identify a
greater number of subjects with CAD, compared to the
ATPIII or IDF criteria. However, among women there was
no difference in the identification of CAD subjects with
respect to the three definitions used.
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